Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCG vaccine (SSI) + TDaP-IPV vaccine
- Development stage
- Unknown
- Lead developer
- Radboud University Medical Center
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intramuscular
01
Overview
BCG vaccine (SSI) + TDaP-IPV vaccine is a combination immunization regimen being investigated by the Radboud University Medical Center for its potential to enhance immune responses through heterologous effects. This specific intervention involves the co-administration of the live-attenuated Bacillus Calmette-Guérin (BCG) vaccine (SSI strain) alongside the standard Tetanus, Diphtheria, acellular Pertussis, and Inactivated Poliovirus (TDaP-IPV) booster. The primary objective of this approach, particularly in the context of whooping cough (pertussis) and tuberculosis, is to investigate whether BCG-induced "trained immunity"—characterized by the epigenetic and metabolic reprogramming of innate immune cells—can boost the specific adaptive immune response to the pertussis antigens contained within the TDaP-IPV vaccine. This research explores the broader application of BCG beyond its traditional role in tuberculosis prevention to improve the efficacy of other routine vaccinations.
- Brand names
- BCG Vaccine SSI
- Other names
- BCG vaccine (SSI) + Tetanus, Diphtheria, acellular Pertussis, and Inactivated Poliovirus vaccineBCG as a Booster for TDaP-IPV Vaccination
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)TLR4 (Toll-like receptor 4)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)PV3 (Sabin) (Poliovirus type 3 antigen)TT (Tetanus toxoid)
Beyond the preview
Go deeper on BCG vaccine (SSI) + TDaP-IPV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCG vaccine (SSI) + TDaP-IPV vaccine.